Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651252 | 0.97 | MET (0.49) | METTSHRLMNASMN1; SMN2HTR3A | |
| SCHEMBL5653274 | 0.94 | TSHR (0.52) | METTSHRLMNASMN1; SMN2HTR3A | |
| SCHEMBL5653202 | 0.93 | MET (0.51) | METTSHRLMNASMN1; SMN2HTR3A | |
| SCHEMBL5652221 | 0.91 | TNKS2 (0.49) | METTSHRLMNASMN1; SMN2HTR3A | |
| SCHEMBL5651675 | 0.91 | MET (0.51) | METLMNASMN1; SMN2CYP2D6CYP2C9 | |
| SCHEMBL5653211 | 0.90 | MET (0.51) | METTSHRLMNASMN1; SMN2HTR3A | |
| SCHEMBL5652228 | 0.89 | TNKS2 (0.49) | METTSHRLMNASMN1; SMN2HTR3A | |
| SCHEMBL5652745 | 0.89 | MET (0.52) | METTSHRLMNASMN1; SMN2HTR3A | |
| SCHEMBL5648993 | 0.88 | CYP2D6 (0.58) | METTSHRLMNASMN1; SMN2KMT2A | |
| SCHEMBL5648730 | 0.88 | HDAC3 (0.51) | TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | MET 1722/4885TSHR 161/4885LMNA 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.